Teladoc Health (NYSE:TDOC) Releases Q4 2026 Earnings Guidance

Teladoc Health (NYSE:TDOC) issued an update on its fourth quarter 2026 earnings guidance on Friday. The company provided earnings per share guidance of -0.230–0.030 for the period, compared to the consensus EPS estimate of -0.090. The company issued revenue guidance of $569.0 million-$615.0 million, compared to the consensus revenue estimate of $601.7 million. Teladoc Health also updated its FY 2026 guidance to -0.950–0.750 EPS.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Teladoc Health in a research note on Wednesday, August 19th. Canaccord Genuity Group decreased their price target on shares of Teladoc Health from $11.00 to $10.00 and set a “buy” rating on the stock in a report on Thursday, July 30th. Citigroup dropped their target price on Teladoc Health from $11.00 to $7.50 and set a “neutral” rating for the company in a research report on Monday, August 3rd. Bank of America increased their price target on shares of Teladoc Health from $9.00 to $10.50 and gave the company a “buy” rating in a research report on Tuesday, July 7th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Teladoc Health in a research note on Thursday. Five analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $7.54.

Teladoc Health Stock Performance

Shares of NYSE:TDOC traded down $0.14 during midday trading on Friday, reaching $8.60. 2,964,080 shares of the company’s stock traded hands, compared to its average volume of 5,085,994. Teladoc Health has a one year low of $4.40 and a one year high of $9.89. The company has a market cap of $1.56 billion, a price-to-earnings ratio of -10.02 and a beta of 2.14. The stock has a 50 day moving average of $6.19 and a 200 day moving average of $6.47.

Teladoc Health (NYSE:TDOC) last issued its quarterly earnings data on Wednesday, October 28th. The health services provider reported ($0.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.07. Teladoc Health had a negative net margin of 6.27% and a negative return on equity of 11.52%. The company had revenue of $605.10 million for the quarter, compared to the consensus estimate of $588.14 million. During the same quarter in the prior year, the firm earned ($0.28) earnings per share. The firm’s revenue for the quarter was down 3.4% compared to the same quarter last year. Sell-side analysts predict that Teladoc Health will post -0.92 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Charles III sold 17,805 shares of the firm’s stock in a transaction dated Friday, September 11th. The stock was sold at an average price of $6.10, for a total value of $108,610.50. Following the transaction, the chief executive officer owned 465,535 shares of the company’s stock, valued at $2,839,763.50. This trade represents a 3.68% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 0.70% of the company’s stock.

Key Stories Impacting Teladoc Health

Here are the key news stories impacting Teladoc Health this week:

• Positive Sentiment: Teladoc reported third-quarter revenue of $605.1 million, down approximately 3% year over year but above Wall Street expectations. Its $0.15 per-share loss was also narrower than the roughly $0.22-$0.23 consensus estimate. Teladoc Health Reports Third Quarter 2026 Results
• Positive Sentiment: Adjusted EBITDA reached approximately $79 million, exceeding guidance, while improving free cash flow supported the view that Teladoc’s earnings quality and financial discipline are strengthening. Teladoc Health Stock Rebounds on Q3 Results
• Positive Sentiment: BetterHelp’s insurance-related revenue reached $32 million, giving investors early evidence that the mental-health business can diversify beyond direct consumer payments. Teladoc also outlined a plan to exit certain insurance arrangements at a run rate of at least $200 million and repurchase convertible notes. Teladoc Targets BetterHelp Insurance Exit Run Rate
• Neutral Sentiment: Teladoc’s full-year 2026 revenue outlook of $2.4 billion is in line with consensus. The company issued an EPS range of a $0.95 loss to a $0.75 loss, broadly surrounding the $0.81 consensus estimate. Teladoc Provides 2026 Guidance
• Negative Sentiment: Fourth-quarter revenue guidance of $569 million to $615 million has a midpoint below the $601.7 million analyst estimate, while the EPS range of a $0.23 loss to a $0.03 loss indicates that near-term profitability remains uncertain. Analysts have generally maintained “hold” ratings, with at least one price target below the recent trading level. Teladoc Stock Rallies After Q3 Beat

Teladoc Health Company Profile

Teladoc Health, Inc provides virtual healthcare services and technology designed to connect patients with medical professionals remotely. Through its digital platforms, the company supports a range of healthcare needs, including general medical consultations, mental health services, specialty care, and ongoing management of chronic conditions.

Its offerings include telehealth visits with physicians and other licensed providers, behavioral health services through BetterHelp, and chronic care programs that use digital tools and clinical support to help people manage conditions such as diabetes and hypertension.